首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial
【24h】

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial

机译:3至5年预定的CEA和CT后续的影响检测结直肠癌的复发性:FACS随机临床试验

获取原文
获取原文并翻译 | 示例
       

摘要

IMPORTANCE: Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence. OBJECTIVE: To assess the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial in 39 National Health Service hospitals in the United Kingdom; 1202 eligible participants were recruited between January 2003 and August 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation. INTERVENTIONS: Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300), CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years; CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years; and the minimum follow-up group received follow-up if symptoms occurred. MAIN OUTCOMES AND MEASURES: The primary outcome was surgical treatment of recurrence with curative intent; secondary outcomes were mortality (total and colorectal cancer), time to detection of recurrence, and survival after treatment of recurrence with curative intent. RESULTS: After a mean 4.4 (SD, 0.8) years of observation, cancer recurrence was detected in 199 participants (16.6%; 95% CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95% CI, 4.6%-7.2%) were treated for recurrence with curative intent, with little difference according to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical treatment of recurrence with curative intent was 2.3% (7/301) in the minimum follow-up group, 6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the CEA+CT group. Compared with minimum follow-up, the absolute difference in the percentage of patients treated with curative intent in the CEA group was 4.4% (95% CI, 1.0%-7.9%; adjusted odds ratio [OR], 3.00; 95% CI, 1.23-7.33), in the CT group was 5.7% (95% CI, 2.2%-9.5%; adjusted OR, 3.63; 95% CI, 1.51-8.69), and in the CEA+CT group was 4.3% (95% CI, 1.0%-7.9%; adjusted OR, 3.10; 95% CI, 1.10-8.71). The number of deaths was not significantly different in the combined intensive monitoring groups (CEA, CT, and CEA+CT; 18.2% [164/901]) vs the minimum follow-up group (15.9% [48/301]; difference, 2.3%; 95% CI, -2.6% to 7.1%). CONCLUSIONS AND RELEVANCE: Among patients who had undergone curative surgery for primary colorectal cancer, intensive imaging or CEA screening each provided an increased rate of surgical treatment of recurrence with curative intent compared with minimal follow-up; there was no advantage in combining CEA and CT. If there is a survival advantage to any strategy, it is likely to be small. TRIAL REGISTRATION: isrctn.org Identifier: 41458548
机译:重要性:结直肠癌手术后的密集随访是常见的做法,但基于有限的证据。目的:评估癌症血液抗原(CEA)和计算断层摄影(CT)的调度血液测量的影响,以检测与治疗意图可治疗的复发结直肠癌。设计,环境和参与者:39个国家卫生服务医院的随机临床试验; 1202符合条件的参与者于2003年1月至2009年期间招聘,该参与者在2009年8月之间进行了对原发性结肠直肠癌的疗法手术,包括佐剂治疗,如果指出,没有关于调查的残留疾病的证据。干预措施:参与者被随机分配给4组中的1个:CEA仅(n = 300),仅限CT(n = 299),CEA + CT(n = 302),或最小随访(n = 301)。血液CEA每3个月测量2年,然后每6个月持续3年;胸部,腹部和骨盆的CT扫描每6个月进行2年,然后每年进行3年;如果发生症状,则收到的最低后续组。主要成果和措施:主要结果是治疗意图的复发外科治疗;二次结果是死亡率(总和结直肠癌),检测复发的时间,治疗复发后的存活率。结果:在观察的平均4.4(SD,0.8)年后,199名参与者中检测到癌症复发(16.6%; 95%CI,14.5%-18.7%);参与者中的71名(5.9%; 95%CI,4.6%-7.2%)与治疗意图进行复发,根据Dukes分期差异很小(阶段a,5.1%[13/254]; b,6.1% [34/553];第C,6.2%[22/354])。在CEA组的最低后续组,6.7%(20/300)中,在CEA组的最低后续组,8%(24/299)中,在CEA组中的6.7%(20/300)和6.6% (20/302)在CEA + CT组中。与最小随访相比,CEA组治疗患者患者百分比的绝对差异为4.4%(95%CI,1.0%-7.9%;调整赔率比[或],3.00; 95%CI, 1.23-7.33),在CT组中为5.7%(95%CI,2.2%-9.5%;调整或3.63; 95%CI,1.51-8.69)和CEA + CT组为4.3%(95%) CI,1.0%-7.9%;调整或3.10; 95%CI,1.10-8.71)。组合的密集监测组(CEA,CT和CEA + CT中死亡人数没有显着差异。18.2%[164/901])与最低后续组(15.9%[48/301];差异, 2.3%; 95%CI,-2.6%至7.1%)。结论和相关性:对原发性结直肠癌治愈性手术的患者,密集的成像或CEA筛查,每个筛选增加了与疗效的手术治疗与治疗意图相比增加的速率增加了与最小的随访;结合CEA和CT没有优势。如果任何策略存在生存优势,那就可能很小。试用注册:ISRCTN.ORG标识符:41458548

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号